Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides
Open accessPublished version of a preprint
Abstract
The regulation of cellular processes by ion channels has become central to the study of cancer mechanisms. Designing molecules that can modify ion channels specific to tumor cells is a promising area of targeted drug delivery and therapy. Despite their potential in drug discovery, venom peptides—a group of natural products—have largely remained understudied and under-characterized. In general, venom peptides display high specificity and selectivity for their target ion channels. Therefore, they may represent an effective strategy for selectively targeting the dysregulation of ion channels in tumor cells. This review examines existing venom peptide therapies for different cancer types and focuses on the application of snail venom peptides in hepatocellular carcinoma (HCC), the most common form of primary liver cancer worldwide. We provide insights into the mode of action of venom peptides that have been shown to target tumors. We also explore the benefit of using new computational methods like de novo protein structure prediction to screen venom peptides and identify potential druggable candidates. Finally, we summarize the role of cell culture, animal, and organoid models in developing effective therapies against HCC and highlight the need for creating models that represent the most disproportionately affected ethnicities in HCC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764 · see citing works
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · see citing works
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473 · cited 1× · see citing works
“…from needle biopsies of patients; these organoids were reported to signi fi cantly recapitulate the genomic and histologic features of the parent tumor tissue in long-term culture, propagate in immunode fi cient mice injected with the organoids and show sensitivity to sorafenib treatment (91).”
Background
Flagged first, then by citations
- Authors
- Achimba, F., Faezov, B., Cohen, B., Dunbrack, R., & Holford, M.
- Affiliations
- The Graduate Center, CUNY (US)
- Fox Chase Cancer Center (US)
- City University of New York (US)
- Corresponding author
- Holford, Mandë
- Venue
- Molecular Cancer Therapeutics
- Published
- 2023-11-28
- Volume
- 23
- Issue
- 2
- Pages
- 139-147
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC10831335
- OpenAlex
- W4389081329
- Cited by
- 6
- References
- 4
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U54 CA221704(5))
- Common Fund (1DP1AT012812-01)
- National Institute of General Medical Sciences (R35 GM122517)
- Division of Cancer Epidemiology and Genetics, National Cancer Institute (U54CA221704 & U54CA221705)
- Topics
- Health Sciences › Medicine › Pharmacology › Healthcare and Venom Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Venomous Animal Envenomation and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- venom peptides, ion channels, hepatocellular carcinoma, liver tumors, targeted cancer therapy, de novo protein structure prediction, organoid models, animal models, ethnic disparities in cancer
- MeSH terms
- Animals, Carcinoma, Hepatocellular, Ion Channels, Liver Neoplasms, Peptides, Venoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review